KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R Howard, Anna Hockaday, Julia M Brown, Sharon Jackson, Natasha Greatorex, Phoebe Templeton, Michael Tupper, David Phillips, Sonam Yaqub, Di Mortimer, David Stones, Piers E M Patten, Andrew Rawstron, Peter Hillmen, Talha Munir

Br J Haematol 208(5) 1596-1607

PMID41912408
PMCIDPMC13176521
DOI10.1111/bjh.70416
发表日期2026-03-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE 5:生活质量量表图。
摘要

摘要

Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimens (FLAIR) demonstrated improved progression-free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL). This report presents the secondary end-point of health-related quality of life (HR-QoL). FLAIR was a phase 3, open-label, randomised trial across 101 hospitals. Eligible patients were aged 18-75 years, World Health Organization performance status (PS) ≤2, requiring treatment; those with >20% 17p deletion were excluded. IR was administered for up to 6 years and FCR for six cycles. Participants completed European Organisation for Research and Treatment of Cancer Quality of Life C30 Questionnaire (EORTC-QLQ-C30), QLQ CLL Module (QLQ-CLL16), three-level EQ-5D (EQ-5D-3L) and EQ5D visual analogue (EQ-VAS) at baseline and follow-up. Function and symptom trajectories were analysed using repeated-measures multilevel regression. 84.4% of participants completed baseline questionnaires and subsequent compliance was 67.6%-83.5%. Median age was 63 years; most participants were white and male. HR-QoL trajectories were similar. FCR recipients had worse scores at end of treatment but recovered thereafter. By 48 months, more FCR-treated participants showed meaningful improvements in several scales. Statistically significant differences (p < 0.05) favoured IR for physical, role and social function; emotional function favoured FCR. Diarrhoea was more common with IR; fatigue and dyspnoea were more common with FCR, though differences did not exceed minimally important thresholds. Overall, scales were comparable between treatment groups, indicating that continuous IR does not compromise HR-QoL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Mean scores adjusted for baseline for (A) EQ‐5D Utility Index and (B) EQ‐VAS. EQ‐VAS, EQ5D visual analogue; UI, EQ5D‐3L Utility Index.
非 KM Figure
FIGURE 2Mean scores adjusted for baseline for (A) EORTC QLQ C30 functioning scales, (B) EORTC QLQ C30 symptom scales and (C) EORTC QLQ CLL16 symptom scales. EORTC, European Organisation for Research and Treatment of Cancer; FCR, fludarabine, cyclophosphamide and rituximab; GHS–QoL, global health status–quality of life; IR, ibrutinib and rituximab; QLQ‐C30, Quality of Life C30 Questionnaire; QLQ‐CLL16, QLQ CLL Module.
非 KM Figure
FIGURE 3Distribution of changes (declined, improved and remained) in HR‐QoL scales between baseline and 48 m post‐randomisation in (A) FCR and (B) IR. AP, appetite loss; CF, cognitive functioning; CO, constipation; DI, diarhoea; DSE, disease effects; DY, dyspnoea; EF, emotional functioning; EQ‐VAS, EQ5D visual analogue; FA(C30), fatigue; FA(CLL16), fatigue; FH, future health; FI, financial problems; HR‐QoL, health‐related quality of life; IN, infection; NV, nausea/vomiting; PA, pain; PF, physical functioning; QL, global health status/QoL; RF, role functioning; SF, social functioning; SL, insomnia; SP, social problems; TSE, treatment side effects; UI, EQ5D‐3L Utility Index.
非 KM Figure
FIGURE 4Differences as estimated from repeated measures multi‐level regression models in functioning scales for IR compared with FCR up to month 48. A positive change denotes improvement for the functioning scales of the EORTC QLQ‐C30 (including GHS–QoL) and the EQ‐5D‐3L (Utility Index and VAS). The difference in least‐squares means is in favour of the IR group versus the FCR group when showing positive differences for functioning scales and GHS–QoL. EORTC, European Organisation for Research and Treatment of Cancer; FCR, fludarabine, cyclophosphamide and rituximab; GHS–QoL, global health status–quality of life; IR, ibrutinib and rituximab; QLQ‐C30, Quality of Life C30 Questionnaire.
非 KM Figure
FIGURE 5Differences as estimated from repeated measures multilevel regression models in symptom scales for IR compared with FCR up to month 48. A negative change denotes an improvement for the symptom scales of the EORTC QLQ‐C30 and EORTC QLQ‐CLL16. The difference in least‐squares means is in favour of the IR group versus the FCR group when showing negative differences for symptom scales. EORTC, European Organisation for Research and Treatment of Cancer; FCR, fludarabine, cyclophosphamide and rituximab; IR, ibrutinib and rituximab; QLQ‐C30, Quality of Life C30 Questionnaire; QLQ‐CLL16, QLQ CLL Module.
非 KM Figure